VRDN
Viridian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.92
−0.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 71.1M | 70.8M | 302.0K | 314.0K | 1.8M |
| Cost of Revenue | 320.0K | — | — | — | — |
| Gross Profit | 70.8M | 70.8M | 302.0K | 314.0K | 1.8M |
| Operating Expenses | |||||
| R&D Expense | 324.7M | 338.9M | 238.3M | 159.8M | 100.9M |
| SG&A Expense | 151.7M | 95.3M | 61.1M | 95.0M | 35.2M |
| General & Admin Expense | 151.7M | 95.3M | 61.1M | 95.0M | 35.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (320.0K) | — | — | — | — |
| Total Operating Expenses | 476.0M | 434.2M | 299.3M | 254.8M | 136.1M |
| Cost and Expenses | 476.3M | 434.2M | 299.3M | 254.8M | 136.1M |
| Operating Income (EBIT) | (405.2M) | (363.4M) | (299.0M) | (254.4M) | (134.3M) |
| Non-Operating | |||||
| Interest Income | 29.7M | 27.4M | 32.1M | 18.6M | 4.9M |
| Interest Expense | 18.9M | 4.9M | 3.0M | 1.8M | 486.0K |
| Net Interest Income | 10.7M | 22.5M | 29.1M | 16.7M | 4.4M |
| Other Non-Op Income/Expense | 18.2M | 20.8M | 29.1M | 16.7M | 4.4M |
| Non-Operating Income (excl Interest) | (37.2M) | (25.7M) | (32.1M) | (18.6M) | (4.9M) |
| EBT (Pre-Tax Income) | (387.0M) | (342.6M) | (269.9M) | (237.7M) | (129.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (387.0M) | (342.6M) | (269.9M) | (237.7M) | (129.9M) |
| Earnings from Cont. Ops | (387.0M) | (342.6M) | (269.9M) | (237.7M) | (129.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (349.3M) | (281.9M) | (269.9M) | (237.7M) | (129.9M) |
| Per Share | |||||
| Basic EPS | ($3.53) | ($3.32) | ($3.98) | ($5.31) | ($3.91) |
| Diluted EPS | ($3.53) | ($3.32) | ($3.98) | ($5.31) | ($3.91) |
| Revenue Per Share | $0.66 | $0.84 | $0.00 | $0.01 | $0.06 |
| Shares | |||||
| Basic Shares Outstanding | 107.9M | 84.8M | 67.9M | 44.8M | 32.1M |
| Diluted Shares Outstanding | 107.9M | 84.8M | 67.9M | 44.8M | 32.1M |
| Profitability Metrics | |||||
| EBITDA | (368.0M) | (337.2M) | (265.7M) | (235.4M) | (129.1M) |
| D&A | 8.0K | 460.0K | 1.2M | 522.0K | 255.0K |
| EBIT | (368.0M) | (337.7M) | (266.9M) | (235.9M) | (129.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026